---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008477"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:36:14.861825+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Reports Q1 2022 Financial Results, Provides Clinical Updates for Evorpacept

## Summary
- First patient dosed in Phase 2/3 ASPEN-06 study evaluating evorpacept in HER2-positive gastric/GEJ cancer.
- FDA granted Orphan Drug Designation to evorpacept for treatment of gastric/GEJ cancer.
- Cash, cash equivalents and investments totaled $341.7 million as of March 31, 2022, expected to fund operations through mid-2024.
- GAAP net loss for Q1 2022 was $24.5 million ($0.60 per share), compared to $14.2 million ($0.35 per share) in Q1 2021.
- Appointed Itziar Canamasas, Ph.D. to its Board of Directors in April 2022.

## SEC filing metadata
- accession: 0000950170-22-008477
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017022008477/0000950170-22-008477-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017022008477/alxo-20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008477
- JSON: https://secwatch.observer/filing/0000950170-22-008477.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008477.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.